Natural history of the pancreatic remnant after resection of Ipmn: preliminary results from a multi-institutional international study

Abstract

surgical treatment were found in the registry, differed more than a factor 3. The median survival for best supportive care was 3 months, 7 months for medical treatment (Sorafenib) (n = 134), and 17 months for chemoembolization (n = 123). Patients planned for active medical treatment varied between regions (32e53%). Conclusions: In spite of a national treatment programme, regional differences are present with regard to treatment allocation, which requires further efforts to ensure that patients are offered best possible option. Since active treatment improved survival, further options to increase survival are needed. Including improved quality of, and the number of HCC detected by, surveillance, and also increase the number of patients treated with curative intent by downsizing strategies.